November 19, 2015
1 min read
Save

Schema therapy cost-effective for personality disorders

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recent findings indicate cost-effectiveness of schema therapy, but not clarification-oriented psychotherapy, for personality disorders.

To compare cost-effectiveness and cost-utility of schema therapy, clarification-oriented psychotherapy and treatment as usual for individuals with avoidant, dependent, obsessive-compulsive, paranoid, histrionic and/or narcissistic personality disorder from a societal perspective, Lotte L. M. Bamelis, PhD, of Maastricht University, the Netherlands, and colleagues conducted a multicenter, randomized controlled trial between May 2006 and December 2011. They randomly assigned 320 individuals, diagnosed with DSM-IV personality disorders, to received schema therapy (n = 145), treatment as usual (n = 134) or clarification-oriented psychotherapy (n = 41). Costs were measured by interview and patient registries over 36 months. The proportion of recovered patients was measured with the Structured Clinical Interview for DSM-IV Axis II Personality Disorders.

Schema therapy was dominant over treatment as usual and clarification-oriented psychotherapy due to greater clinical efficacy and lower costs, according to researchers.

Treatment as usual was more cost-effective than clarification-oriented psychotherapy due to lower costs.

In cost-utility analyses, schema therapy had a stable 75% probability of being cost-effective, the researchers reported. These findings were confirmed by sensitivity analyses.

As a result, the researchers concluded that cost-effectiveness of schema therapy was supported by their analyses, however, cost-effectiveness of clarification-oriented psychotherapy was not.  – by Amanda Oldt

Disclosure: Please see the full study for a list of all authors’ relevant financial disclosures.